ArticleImmunology and cell biology2021
SARS-CoV-2-specific CD8
Article in Immunology and cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2.Virus research · 2023Pooled it
- Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.JCI insight · 2026Article
- N-terminal pyroglutamylation of an HLA-A24-restricted immunodominant epitope enhances SARS-CoV-2-specific T-cell responses.Frontiers in immunology · 2026Article
- Shared HLA-E and Mamu-E Peptide Repertoires With Subtle Peptide Binding Differences Revealed by Combined nDSF- and Fluorescence Polarisation-Based Methods.European journal of immunology · 2026Article
- HLA-B*15:01-positive severe COVID-19 patients lack CD8Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8European journal of immunology · 2025Article
- Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease.Frontiers in immunology · 2025Article
- Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.Frontiers in immunology · 2025Article
- SARS-CoV-2 spike-specific nasal-resident CD49aNature communications · 2024Article
- SARS-CoV-2-specific CD8Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Scientific highlights of the 9th ESWI Influenza Conference.One health outlook · 2024Article
- Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein.Frontiers in immunology · 2024Article
- The molecular mechanisms of CD8Frontiers in immunology · 2024Review
- Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.Open forum infectious diseases · 2023Article
- Article
- Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.Nature immunology · 2023Article
- Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.Cell reports. Medicine · 2023Article
- Article
- Phenotypic and functional characterization of pharmacologically expanded Vγ9Vδ2 T cells in pigtail macaques.iScience · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
In-depth understanding of human T-cell-mediated immunity in coronavirus disease 2019 (COVID-19) is needed if we are to optimize vaccine strategies and immunotherapies. Identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell epitopes and generation of peptide-human leukocyte antigen (peptide-HLA) tetramers facilitate direct ex vivo analyses of SARS-CoV-2-specific T cells and their T-cell receptor (TCR) repertoires. We utilized a combination of peptide prediction and in vitro peptide stimulation to validate novel SARS-CoV-2 epitopes restricted by HLA-A*24:02, one of the most prominent HLA class I alleles, especially in Indigenous and Asian populations. Of the peptides screened, three spike-derived peptides generated CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.